CClinicalTrials.gg
Not yet recruitingNCT07211945SOLETEUpdated Nov 26, 2025

Loneliness as Risk Factor for Dementia

An observational study in Mild Cognitive Impairment (MCI), Dementia (Diagnosis) and Loneliness, sponsored by Consorci Sanitari de l'Alt Penedès i Garraf. Not yet recruiting at 1 site in Spain. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2025-11-26.

Sponsored by Consorci Sanitari de l'Alt Penedès i Garraf · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
70 Years and older
Sex
All
01

Study summary

This study aims to determine whether loneliness is associated with a higher incidence of dementia in older adults with a prior diagnosis of mild cognitive impairment after 12 months of follow-up.

02

Conditions studied

  • Mild Cognitive Impairment (MCI)
  • Dementia (Diagnosis)
  • Loneliness

Keywords

  • Cognitive Dysfunction
  • Dementia
  • Loneliness
03

In context

Cognitive Dysfunction

3,843 studies on the registry are indexed under Cognitive Dysfunction; 1,100 are open to participants now.

This study's planned enrollment of 300 is above the median of 150 across 950 observational studies indexed under Cognitive Dysfunction.

Browse Cognitive Dysfunction studies →

Lead sponsor

Consorci Sanitari de l'Alt Penedès i Garraf is the lead sponsor of 36 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Older people affected by mild cognitive impairment

Inclusion criteria

Patients may be included in the study if they meet all of the following criteria:

Men and women aged 70 years or older.

Diagnosis of mild cognitive impairment according to Petersen's criteria within the past 12 months.

Follow-up of the condition under study at the Alzheimer's Disease and Other Dementias Unit of Garraf (UMAG) at the Consorci Sanitari Alt Penedès-Garraf (CSAPG).

Expected follow-up of the condition at the study center.

Ability to collaborate in the required assessments.

Legal capacity to provide informed consent.

Signed informed consent for inclusion in the study, either by the participant or their legal representative.

Exclusion criteria

Exclusion criteria

Participants will be excluded from the trial if they meet any of the following criteria:

Diagnosis of any of the following conditions:

Dementia: the evaluating physician will rely on the diagnostic criteria of the Spanish Society of Neurology (SEN) and the results of the neuropsychological assessment performed at the UMAG.

Participation in another study involving an experimental intervention during the present trial period and/or requiring a visit schedule incompatible with this trial.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No

Groups and cohorts

  • Loneliness positive

    Patients with mild cognitive impairment (MCI) and loneliness

  • Loneliness negative

    Patients with mild cognitive impairment (MCI) without loneliness

06

What researchers measure

Primary outcomes

  1. Dementia

    Number of patients who show clinical progress from MCI to dementia

    Time frame: 12 months

07

Study locations

1 site
  • Hospital Sant Antoni Abat
    Vilanova i la Geltrú, Barcelona, Spain
    • Noemí Casaponsa · Contact · recerca@csapg.cat · +34 938960025
    • Carlos Javier Fernández Noa · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — IPD (without personal identification data) could be shared by requirement from other researchers after the end of the study, and only for research purposes and previous approval of promotor center of the study (CSAPG). Anyway, Spanish and European Union legal policy about data protection will strictly be followed (IPD will not be transferred outside European Union).

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07211945
Lead sponsor
Consorci Sanitari de l'Alt Penedès i Garraf
Responsible party
Sponsor
First posted
Oct 8, 2025
Start date
Mar 2026 (estimated)
Primary completion
Sep 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Nov 26, 2025

Study contacts

Noemí Casaponsa
Contact
recerca@csapg.cat
+34 938960025 ext. 43197

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion